Zoran Veličković
MD, Internal Medicine Specialist
Country: Serbia
Zoran is a Internal Medicine Specialist at Institute of Rheumatology, School of Medicine, University of Belgrade, undertaking a PhD at the same institution. His work primarily focuses on investigating the adjunctive treatment for fibromyalgia such as transcranial magnetic stimulation and its influence on different outcomes, such as gait and balance. Wearable sensors and biomechanics of musculoskeletal system are his area of interest.
Zoran is a member of the Country Liaison Sub-committee.
E-mail: velickovic.z@yahoo.com
| Poster 0565 | Wednesday 11.06.25 15:30-16:30 PM Session: Poster View I Author: B. van den Bemt (Netherlands) Title: Overview of authorised drugs to be repurposed for the treatment of osteoarthritis: a scoping review of clinical studies  This scoping review maps all clinical research (177 studies, 42+ drugs) repurposing authorized drugs for osteoarthritis (OA), where no disease-modifying treatments exist. It reveals predominantly short-term symptom focus with limited success, identifies promising long-term structure/outcome impacts, and catalogs 24 understudied candidates. This exhaustive landscape analysis is vital to strategically accelerate cost-effective DMOAD discovery. |
| Oral 0056 | Wednesday 11.06.25 17:40-17:50 PM Session: Clinical Abstract Sessions: Bone Health – New Directions Author: A. Musa (UK) Title: A retrospective study on the risk factors associated with atypical and typical fragility fractures This large-scale study (N=20,862) demonstrates that typical and atypical fragility fractures have distinct risk profiles, challenging FRAX™’s undifferentiated approach. Key findings show atypical fractures are strongly linked to prior fracture history, older age, and vitamin D deficiency – factors FRAX™ includes but doesn’t specify for atypical risk. This evidence is critical for developing more precise risk assessment tools and targeted prevention strategies beyond current standards. |
| Poster 1349 | Saturday 14.06.25 10:15–11:45 AM Session: Poster View VIII Author: T. A. Perry (UK) Title: Synovial-Fluid Based Proteomic Signatures of Biological Aging in Knee Osteoarthritis: Identification of Age-Associated Pathways and Predictive Markers using STEpUP OA This large-scale synovial fluid proteomics study (N=1,361, 7,289 proteins) identifies 1,360 age-associated proteins in knee OA, distinct from disease severity. It reveals key aging pathways and develops a robust “biological age” prediction model (r=0.80). Critically, 94 proteins reflect biological aging independently of OA damage. This enables patient stratification by biological age and informs development of age-tailored OA therapeutics. |
| Poster Tour 0319 | Friday 14.06.24 12:30-12:36 PM Clinical Poster Tours: Risk stratification in metabolic bone diseases Author: Martin, M (Italy) Title: Male osteoporosis and screening guidelines: an underestimated disease in aging population This study suggests that OP should be considered in all men when risk factors for low BMD and fractures are present, independently from age, being age sufficient for screening after 60 years of age. |
| Oral 0055 | Wednesday 11.06.25 17:30-17:40 PM Clinical Abstract Sessions: Bone Health – New Directions Author: I. Valter (Estonia) Title: Sustained Efficacy, Safety and Immunogenicity Following Single Switch from Originator Denosumab to FKS518 Proposed Biosimilar in Postmenopausal Women with Osteoporosis (results from the pivotal LUMIADE 3 study) This pivotal phase 3 trial confirms FKS518 as a therapeutic equivalent to originator denosumab for osteoporosis. Critically, it demonstrates that switching mid-treatment to FKS518 maintains identical efficacy (BMD gains), safety (low ISR, no immunogenicity concerns), and tolerability at 78 weeks. This evidence directly supports real-world switching strategies, enabling broader patient access to cost-effective osteoporosis care without compromising outcomes. |
| Poster 0451 | Wednesday 11.06.25 15:30–16:30 PM Session: Poster View I Author: J. Tambiah (USA) Title: Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections over 3 Years in Subjects with Severe Knee Osteoarthritis This Phase 1b trial demonstrates GNSC-001, an intra-articular AAV gene therapy delivering IL-1Ra, was generally safe and well-tolerated in knee OA patients at 6 months. Despite higher target knee AE rates in an open-label steroid regimen group, no treatment-related SAEs occurred. Critically, sustained IL-1Ra expression above target levels was achieved, validating the approach’s potential to overcome previous IL-1 blockade failures via persistent local inhibition. |